OpenLB
Open Library of Bioscience
Advanced Search
BioMed research international
2017;2017 4346576.

Immunotherapy in Gastrointestinal Cancers.

Letizia Procaccio, Marta Schirripa, Matteo Fassan, Loredana Vecchione, Francesca Bergamo, Alessandra Anna Prete, Rossana Intini, Chiara Manai, Vincenzo Dadduzio, Alice Boscolo, Vittorina Zagonel, Sara Lonardi
Author Information
  1. Letizia Procaccio: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  2. Marta Schirripa: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  3. Matteo Fassan: Department of Medicine, Surgical Pathology & Cytopathology Unit, University of Padova, Padova, Italy.
  4. Loredana Vecchione: Division of Molecular Carcinogenesis, Cancer Genomics Center Netherlands, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  5. Francesca Bergamo: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  6. Alessandra Anna Prete: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  7. Rossana Intini: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  8. Chiara Manai: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  9. Vincenzo Dadduzio: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  10. Alice Boscolo: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  11. Vittorina Zagonel: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  12. Sara Lonardi: Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy. ORCID
PMID: 28758114 DOI: 10.1155/2017/4346576

Abstract

Gastrointestinal cancers represent a major public health problem worldwide. Immunotherapeutic strategies are currently under investigation in this setting and preliminary results of ongoing trials adopting checkpoint inhibitors are striking. Indeed, although a poor immunogenicity for GI has been reported, a strong biological rationale supports the development of immunotherapy in this field. The clinical and translational research on immunotherapy for the treatment of GI cancers started firstly with the identification of immune-related mechanisms possibly relevant to GI tumours and secondly with the development of immunotherapy-based agents in clinical trials. In the present review a general overview is firstly provided followed by a focus on major findings on gastric, colorectal, and hepatocellular carcinomas. Finally, pathological and molecular perspectives are provided since many efforts are ongoing in order to identify possible predictive biomarkers and to improve patients' selection. Many issues are still unsolved in this field; however, we strongly believe that immunotherapy might positively affect the natural history of a subgroup of GI cancer patients improving outcome and the overall quality of life.

References

  1. Clin Cancer Res. 2010 Mar 1;16(5):1662-72 [PMID: 20179239]
  2. Science. 2011 Mar 25;331(6024):1565-70 [PMID: 21436444]
  3. BMC Cancer. 2010 May 17;10:209 [PMID: 20478057]
  4. Nat Rev Immunol. 2013 Apr;13(4):227-42 [PMID: 23470321]
  5. J Immunother. 2005 Sep-Oct;28(5):496-504 [PMID: 16113606]
  6. Nature. 2014 Nov 27;515(7528):563-7 [PMID: 25428504]
  7. Immunity. 2016 Mar 15;44(3):698-711 [PMID: 26982367]
  8. J Hepatol. 2012 Oct;57(4):821-9 [PMID: 22727733]
  9. Prog Exp Tumor Res. 1970;13:1-27 [PMID: 4921480]
  10. Pancreas. 2012 Apr;41(3):409-15 [PMID: 22158072]
  11. Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):159-69 [PMID: 23809238]
  12. J Exp Med. 2005 Oct 17;202(8):1075-85 [PMID: 16230475]
  13. Lancet Oncol. 2016 Jun;17(6):717-726 [PMID: 27157491]
  14. Nat Rev Cancer. 2004 Nov;4(11):839-49 [PMID: 15516957]
  15. Lancet Oncol. 2016 Dec;17(12):e542-e551 [PMID: 27924752]
  16. Clin Cancer Res. 2009 Feb 1;15(3):971-9 [PMID: 19188168]
  17. Annu Rev Pathol. 2016 May 23;11:313-41 [PMID: 27193453]
  18. Clin Cancer Res. 2006 May 1;12(9):2817-25 [PMID: 16675576]
  19. Br J Cancer. 2011 Jun 28;105(1):93-103 [PMID: 21629244]
  20. Curr Opin Immunol. 2013 Apr;25(2):230-7 [PMID: 23414607]
  21. Hepatology. 2009 Jan;49(1):124-32 [PMID: 18980227]
  22. J Clin Oncol. 2015 Jun 10;33(17):1974-82 [PMID: 25605845]
  23. Immunity. 2016 Mar 15;44(3):609-621 [PMID: 26944201]
  24. Clin Cancer Res. 2007 Apr 1;13(7):2151-7 [PMID: 17404099]
  25. Elife. 2014 Aug 01;3:e02725 [PMID: 25085081]
  26. J Gastrointest Oncol. 2015 Apr;6(2):208-23 [PMID: 25830040]
  27. J Transl Med. 2012 Oct 03;10:205 [PMID: 23034130]
  28. J Cancer Res Clin Oncol. 2013 Jan;139(1):39-48 [PMID: 22886490]
  29. J Clin Oncol. 2000 Jan;18(1):148-57 [PMID: 10623705]
  30. J Transl Med. 2014 Apr 05;12:86 [PMID: 24708667]
  31. Clin Dev Immunol. 2011;2011:320571 [PMID: 22110523]
  32. Ann Surg. 2012 Jan;255(1):8-17 [PMID: 22104564]
  33. Cancer Control. 2013 Jan;20(1):32-42 [PMID: 23302905]
  34. Crit Rev Oncol Hematol. 2017 Feb;110:106-116 [PMID: 28109400]
  35. Eur J Cancer. 1991;27(6):703-10 [PMID: 1829908]
  36. Cancer Metastasis Rev. 2017 Mar;36(1):179-190 [PMID: 27873079]
  37. Mol Ther. 2010 Apr;18(4):843-51 [PMID: 20179677]
  38. Oncoimmunology. 2016 Jan 19;5(5):e1129483 [PMID: 27467945]
  39. Clin Cancer Res. 2017 Aug 1;23(15):4429-4440 [PMID: 28348045]
  40. Cancer Res. 2015 Aug 1;75(15):3020-31 [PMID: 26116496]
  41. J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [PMID: 14970275]
  42. Lancet Oncol. 2016 Nov;17(11):1558-1568 [PMID: 27622997]
  43. Nature. 2014 Sep 11;513(7517):202-9 [PMID: 25079317]
  44. Hepatogastroenterology. 2014 Mar-Apr;61(130):278-84 [PMID: 24901124]
  45. Clin Cancer Res. 2006 Feb 15;12(4):1144-51 [PMID: 16489067]
  46. Cancer Discov. 2015 Jan;5(1):43-51 [PMID: 25358689]
  47. Expert Opin Drug Metab Toxicol. 2016;12(1):57-75 [PMID: 26565919]
  48. Vaccine. 2001 Mar 21;19(17-19):2576-82 [PMID: 11257395]
  49. Immunity. 2004 Aug;21(2):137-48 [PMID: 15308095]
  50. Cancer Immunol Immunother. 2007 Nov;56(11):1687-700 [PMID: 17571260]
  51. Mol Cancer Ther. 2015 Apr;14(4):847-56 [PMID: 25695955]
  52. Cancer Immunol Immunother. 2007 Jul;56(7):1009-16 [PMID: 17186291]
  53. Inflamm Res. 2013 Sep;62(9):823-34 [PMID: 23868500]
  54. Lancet. 1999 Jan 30;353(9150):345-50 [PMID: 9950438]
  55. Expert Rev Clin Pharmacol. 2017 Jun;10(6):609-619 [PMID: 28349740]
  56. Cancer Res Treat. 2014 Apr;46(2):124-30 [PMID: 24851103]
  57. Int J Oncol. 2012 Nov;41(5):1601-9 [PMID: 22971679]
  58. Clin Cancer Res. 2009 Dec 1;15(23):7412-20 [PMID: 19934295]
  59. J Pathol. 2014 Jan;232(2):199-209 [PMID: 24122236]
  60. Cancer Treat Rev. 2015 Dec;41(10):893-903 [PMID: 26412280]
  61. Cancer Immunol Immunother. 2013 May;62(5):949-54 [PMID: 23589109]
  62. Clin Cancer Res. 2010 May 1;16(9):2646-55 [PMID: 20406835]
  63. Nature. 2002 Dec 19-26;420(6917):860-7 [PMID: 12490959]
  64. World J Gastroenterol. 2014 Apr 14;20(14):3738-50 [PMID: 24833840]
  65. J Natl Cancer Inst. 2016 May 12;108(8): [PMID: 27172904]
  66. J Hematol Oncol. 2013 Sep 30;6(1):74 [PMID: 24283718]
  67. Cancer Immunol Immunother. 2005 Apr;54(4):307-14 [PMID: 15599732]
  68. Cancer Immunol Immunother. 2009 Jan;58(1):61-9 [PMID: 18488223]
  69. Clin Cancer Res. 2012 Jul 1;18(13):3686-96 [PMID: 22577059]
  70. N Engl J Med. 2015 Sep 24;373(13):1270-1 [PMID: 26398076]
  71. Clin Cancer Res. 2011 Jul 1;17(13):4550-7 [PMID: 21498393]
  72. N Engl J Med. 2011 Jun 30;364(26):2517-26 [PMID: 21639810]
  73. Science. 2015 Nov 27;350(6264):1079-84 [PMID: 26541610]
  74. N Engl J Med. 2008 Dec 4;359(23):2497-8; author reply 2498-9 [PMID: 19052134]
  75. N Engl J Med. 2015 Nov 12;373(20):1979 [PMID: 26559582]
  76. Arch Pathol Lab Med. 2016 Mar;140(3):245-8 [PMID: 26927719]
  77. Curr Colorectal Cancer Rep. 2015 Jun 1;11(3):125-140 [PMID: 26441489]
  78. J Hematol Oncol. 2016 Mar 24;9:29 [PMID: 27012666]
  79. Eur J Cancer. 2014 Oct;50(15):2570-82 [PMID: 25091797]
  80. N Engl J Med. 2015 Jun 25;372(26):2521-32 [PMID: 25891173]
  81. Ann N Y Acad Sci. 2013 May;1284:1-5 [PMID: 23651186]
  82. J Hematol Oncol. 2013 Jul 08;6:47 [PMID: 23829929]
  83. J Clin Oncol. 1993 Mar;11(3):390-9 [PMID: 8445413]
  84. J Surg Res. 1981 Apr;30(4):409-15 [PMID: 7230788]
  85. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5902-8 [PMID: 14676113]
  86. Nat Immunol. 2013 Oct;14(10):1014-22 [PMID: 24048123]
  87. Cancer Res. 2014 Jul 1;74(13):3512-24 [PMID: 24812270]
  88. J Hepatol. 2013 Jul;59(1):81-8 [PMID: 23466307]
  89. Cancer Treat Rev. 2014 May;40(4):513-22 [PMID: 24315741]
  90. Curr Opin Gastroenterol. 2013 Sep;29(5):537-43 [PMID: 23892539]
  91. Hepatology. 2000 Jan;31(1):54-8 [PMID: 10613728]
  92. Annu Rev Pathol. 2008;3:157-88 [PMID: 18039136]
  93. J Pathol. 2012 Dec;228(4):586-95 [PMID: 22926706]
  94. Curr Opin Immunol. 2012 Apr;24(2):207-12 [PMID: 22236695]
  95. Cancer Sci. 2013 Apr;104(4):437-44 [PMID: 23298232]

MeSH Term

Biomarkers, Tumor
Gastrointestinal Neoplasms
Humans
Immunotherapy
Translational Research, Biomedical

Chemicals

Biomarkers, Tumor
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0GIimmunotherapyGastrointestinalcancersmajorongoingtrialsdevelopmentfieldclinicalfirstlyprovidedrepresentpublichealthproblemworldwideImmunotherapeuticstrategiescurrentlyinvestigationsettingpreliminaryresultsadoptingcheckpointinhibitorsstrikingIndeedalthoughpoorimmunogenicityreportedstrongbiologicalrationalesupportstranslationalresearchtreatmentstartedidentificationimmune-relatedmechanismspossiblyrelevanttumourssecondlyimmunotherapy-basedagentspresentreviewgeneraloverviewfollowedfocusfindingsgastriccolorectalhepatocellularcarcinomasFinallypathologicalmolecularperspectivessincemanyeffortsorderidentifypossiblepredictivebiomarkersimprovepatients'selectionManyissuesstillunsolvedhoweverstronglybelievemightpositivelyaffectnaturalhistorysubgroupcancerpatientsimprovingoutcomeoverallqualitylifeImmunotherapyCancers

Similar Articles

Cited By